Skip to main content

Rhythm Pharmaceuticals Inc(RYTM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low89.06
Day High89.06
Open:89.06
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Rhythm Pharmaceuticals Inc

Select a category then submit the form to load news
Tipranks
Rhythm Pharmaceuticals Balances Strong Growth With Rising Costs
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Surgery Partners (SGRY)
Tipranks
Analysts’ Top Healthcare Picks: Veeva Systems (VEEV), Omnicell (OMCL)
Motley Fool
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Motley Fool
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Tipranks
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)
Tipranks
Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity
GlobeNewswire
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Tipranks
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Teleflex (TFX)
Motley Fool
Rhythm Pharma (RYTM) Earnings Call Transcript
GlobeNewswire
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Motley Fool
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
Motley Fool
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
Motley Fool
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
GlobeNewswire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Motley Fool
Prediction: These 3 Stocks Will Crush the Market in 2026
Tipranks
Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Motley Fool
This High-Flying Growth Stock Is Hiding in Plain Sight
Tipranks
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Rhythm Pharmaceuticals (RYTM)
Tipranks
Bank of America Securities Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Tipranks
Wells Fargo Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Tipranks
Rhythm Pharmaceuticals (RYTM) Receives a Buy from TD Cowen
Tipranks
Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue
GlobeNewswire
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
Tipranks
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Wells Fargo
Tipranks
Rhythm Pharmaceuticals Announces Resignation of Board Member Bedrosian
Tipranks
Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.